Ionis Pharmaceuticals

Yahoo Finance • 3 months ago

Ionis announces proposed public offering of common stock

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day opti... Full story

Yahoo Finance • 4 months ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Praxis Precision Medicines, Inc. BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for cen... Full story

Yahoo Finance • 5 months ago

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PIERRE trial has been completed. 10 spina... Full story

Yahoo Finance • 7 months ago

Shareholders Will Probably Not Have Any Issues With Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation

Key Insights Ionis Pharmaceuticals' Annual General Meeting to take place on 6th of June Salary of US$960.9k is part of CEO Brett Monia's total remuneration The total compensation is similar to the average for the industry Ionis Pharmaceut... Full story

Yahoo Finance • 8 months ago

Ionis Publishes 2023 Corporate Responsibility Report

Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medi... Full story

Yahoo Finance • 10 months ago

Ionis Pharmaceuticals Inc (IONS) Surpasses Revenue Guidance for 2023, Sets Sights on 2024 Growth

Total Revenue: Increased to $788 million in 2023 from $587 million in 2022. Operating Expenses: Rose to $1,141 million in 2023, reflecting investment in pipeline and technology. Net Loss: Reported a net loss of $366 million in 2023, compar... Full story

Yahoo Finance • 11 months ago

Insider Sell: EVP CLO & General Counsel Patrick O'Neil Sells 7,744 Shares of Ionis ...

Patrick O'Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals Inc (NASDAQ:IONS), has sold 7,744 shares of the company on January 17, 2024, according to a recent SEC filing. The transaction was executed at an average price of $50.42 pe... Full story

Yahoo Finance • last year

12 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can... Full story

Yahoo Finance • last year

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients Ionis plans to independently bring donidalorsen to U.S. patients if approved Donidalorsen Phase 3 results expected in the first... Full story

Yahoo Finance • last year

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

FMC Corp Takes the Spotlight in Tweedy Browne's Latest 13F Filing with a 1.56% Portfolio Impact

Insight into Tweedy Browne (Trades, Portfolio)'s Q3 2023 Investment Moves and Top Holdings Warning! GuruFocus has detected 6 Warning Signs with BRK.A. Renowned for its adherence to the value investing principles of Benjamin Graham, Tweed... Full story

Yahoo Finance • last year

Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Trading At A 29% Discount?

Key Insights Ionis Pharmaceuticals' estimated fair value is US$66.44 based on 2 Stage Free Cash Flow to Equity Ionis Pharmaceuticals is estimated to be 29% undervalued based on current share price of US$47.19 The US$53.93 analyst price ta... Full story

Yahoo Finance • last year

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter... Full story

Yahoo Finance • last year

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec) Biogen also reported new real-world evidence and progress on the development of a no... Full story

Yahoo Finance • 2 years ago

Ionis to present at upcoming investor conferences

CARLSBAD, Calif., May 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Ionis logo with tagline (PRNewsfoto/Ionis Ph... Full story

Yahoo Finance • 2 years ago

Biogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key Endorsement

Biogen stock jumped — as Ionis stock gave back early gains — after a FDA panel offered a mixed view of their ALS treatment. Continue reading... Full story

Yahoo Finance • 2 years ago

Ionis to hold fourth quarter and full year 2022 financial results webcast

Webcast scheduled for Wednesday, February 22 at 11:30 a.m. Eastern Time CARLSBAD, Calif., Feb. 8, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 22nd... Full story

Yahoo Finance • 2 years ago

Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research

CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovati... Full story

Yahoo Finance • 2 years ago

Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsenRoyalty Pharma to pay Ionis $500 million upfront and up to $625 million in mil... Full story

Yahoo Finance • 2 years ago

Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS

SOD1-ALS affects approximately 2% of people living with ALS worldwide1 If approved, tofersen would be the world's first treatment to target a genetic cause of ALS EMA acceptance follows FDA's acceptance of tofersen NDA earlier this year... Full story